CTC levels as a surrogate endpoint for clinical trials in mCRPC

A newly published analysis of data from five major clinical trials involving > 6,000 patients has provided us with additional information about circulating tumor cell (CTC) levels as an endpoint for clinical trials. … READ MORE …

Could “single cell genomics” replace Gleason grading in prostate cancer risk evaluation?

According to a study just published in Cancer Research, a completely new technique referred to as “single cell genomics” may be able to improve the accuracy of diagnosis of prostate cancer based on biopsy tissue. … READ MORE …

Are PCSP cells one of the keys to risk for prostate cancer metastasis?

A newly published paper in the journal called The Prostate has described a type of previously unidentified cell that may indicate the presence of a more aggressive subtype of prostate cancer. … READ MORE …

Of CTCs, EMT, PSA, and megakaryocytes … Huh?

A newly published study in Clinical Cancer Research has implied the potential development of a completely new and much more accurate way to be able to identify risk for metastatic prostate cancer. … READ MORE …

Are we getting closer to understanding why we get prostate cancer?

Every so often we note that we still have little to no really clear idea why men get prostate cancer in the first place (or indeed why any of us get any type of cancer). In this context, some new research from a team at the University of California, Los Angeles, is at least interesting. … READ MORE …

A better way to identify risk for metastasis?

According to a news report on the ScienceDaily web site, researchers in the UK have identified a subgroup of circulating tumor cells (CTCs) in patient’s blood that seem to be linked to risk for progression and spread of prostate cancer. … READ MORE …

A new method to use CTCs to diagnose/assess risk for prostate cancer?

In another breaking story from the UK, a company called Angle PLC has announced that its Parsortix diagnostic system can potentially be used to identify men with prostate cancer using a simple blood sample and testing for the presence of circulating tumor cells (CTCs). … READ MORE …